Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics

Core Insights - Journey Medical Corporation reported revenue of $17.63 million for the quarter ended September 2025, reflecting a year-over-year increase of 20.5% [1] - The earnings per share (EPS) was -$0.09, an improvement from -$0.12 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $17.7 million by 0.39%, while the EPS was below the consensus estimate of -$0.08 by 12.5% [1] Financial Performance Metrics - Total net product revenue for Accutane was $2.77 million, which is 30.7% lower than the year-ago figure and below the average estimate of $3.54 million [4] - Total net product revenue for EmrosiTM was reported at $4.88 million, compared to the estimated $6.35 million, indicating a significant shortfall [4] - Total net product revenue for Qbrexza was $7.36 million, slightly exceeding the estimated $6.67 million, but still showing a year-over-year decline of 2.9% [4] Stock Performance - Journey Medical's shares have increased by 25.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]